Anti-IL-5 Therapy, Mepolizumab, Shows Promise in COPD Management
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on May 28th, 2025
|
Eosinophilic inflammation plays a significant role in chronic obstructive pulmonary disease (COPD), with interleukin-5 (IL-5) driving eosinophil maturation and activation. To evaluate a targeted approach, GlaxoSmithKline sponsored a study examining the efficacy of mepolizumab—an anti-IL-5 monoclonal antibody—in managing COPD.
The phase 3 clinical trial enrolled 804 participants with an average age of 66, all of whom were receiving inhaled triple therapy for COPD. At baseline, the mean blood eosinophil count was approximately 480 cells per microliter. Participants were randomly assigned to receive either a placebo or 100 mg of mepolizumab via subcutaneous injection every four weeks. After 104 weeks of treatment, mepolizumab reduced the risk of moderate-to-severe COPD exacerbations requiring hospitalization, systemic corticosteroids, or antibiotics by 21% compared to placebo. Furthermore, the time to first exacerbation was significantly delayed in the mepolizumab group. However, no notable improvements were observed in symptom severity or quality of life, as measured by the SGRQ, E-RS-COPD, and CAT assessment tools. While mepolizumab showed promise in reducing exacerbation frequency, its limited impact on patient-reported outcomes suggests a need for further research. As evidence grows supporting the role of type 2 inflammation modulators in COPD management, comparative studies may help delineate the specific therapeutic roles of each agent.
The phase 3 clinical trial enrolled 804 participants with an average age of 66, all of whom were receiving inhaled triple therapy for COPD. At baseline, the mean blood eosinophil count was approximately 480 cells per microliter. Participants were randomly assigned to receive either a placebo or 100 mg of mepolizumab via subcutaneous injection every four weeks. After 104 weeks of treatment, mepolizumab reduced the risk of moderate-to-severe COPD exacerbations requiring hospitalization, systemic corticosteroids, or antibiotics by 21% compared to placebo. Furthermore, the time to first exacerbation was significantly delayed in the mepolizumab group. However, no notable improvements were observed in symptom severity or quality of life, as measured by the SGRQ, E-RS-COPD, and CAT assessment tools. While mepolizumab showed promise in reducing exacerbation frequency, its limited impact on patient-reported outcomes suggests a need for further research. As evidence grows supporting the role of type 2 inflammation modulators in COPD management, comparative studies may help delineate the specific therapeutic roles of each agent.